Indeterminate Colitis – Update on Treatment Options

Niranjani Venkateswaran,1 Scott Weismiller,1 Kofi Clarke2 1Division of General Internal Medicine, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA; 2Division of Gastroenterology and Hepatology, Department of Medicine, Pennsylvania State University College o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Venkateswaran N, Weismiller S, Clarke K
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/874a0d0a449f4db6a25aff55a1d8e405
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:874a0d0a449f4db6a25aff55a1d8e405
record_format dspace
spelling oai:doaj.org-article:874a0d0a449f4db6a25aff55a1d8e4052021-11-30T18:50:37ZIndeterminate Colitis – Update on Treatment Options1178-7031https://doaj.org/article/874a0d0a449f4db6a25aff55a1d8e4052021-11-01T00:00:00Zhttps://www.dovepress.com/indeterminate-colitis--update-on-treatment-options-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Niranjani Venkateswaran,1 Scott Weismiller,1 Kofi Clarke2 1Division of General Internal Medicine, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA; 2Division of Gastroenterology and Hepatology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USACorrespondence: Kofi ClarkeDivision of Gastroenterology and Hepatology, Department of Medicine, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA, 17033, USATel +1 717-531-8741Fax +1 717-531-6770Email kclarke@pennstatehealth.psu.eduAbstract: Indeterminate colitis (IC) is described in approximately 5– 15% of patients with inflammatory bowel disease (IBD). It usually reflects a difficulty or lack of clarity in distinguishing between ulcerative colitis (UC) and Crohn’s disease (CD) on biopsy or colectomy specimens. The diagnostic difficulty may explain the variability in the reported prevalence and incidence of IC. Clinically, most IC patients tend to evolve over time to a definite diagnosis of either UC or CD. IC has also been interchangeably described as inflammatory bowel disease unclassified (IBDU). This review offers an overview of the available limited literature on the conventional medical and surgical treatments for IC. In contrast to the numerous studies on the medical management of UC and CD, there are very few data from dedicated controlled trials on the treatment of IC. The natural evolution of IC more closely mimics UC. Regarding medical options for treatment, most patients diagnosed with IC are treated similarly to UC, and treatment choices are based on disease severity. Others are managed similarly to CD if there are features suggestive of CD, including fissures, skin tags, or rectal sparing. In medically refractory IC, surgical treatment options are limited and include total proctocolectomy (TPC) and ileal pouch–anal anastomosis (IPAA), with its associated risk factors and complications. Post-surgical complications and pouch failure rates were historically thought to be more common in IC patients, but recent meta-analyses reveal similar rates between UC and IC patients. Future therapies in IBD are focused on known mechanisms in the disease pathways of UC and CD. Owing to the lack of IC-specific studies, clinicians have traditionally and historically extrapolated the data to IC patients based on their symptomatology, clinical course, and endoscopic findings.Keywords: indeterminate colitis, medical treatment, ulcerative colitis, Crohn’s disease, total proctocolectomy, ileal pouch–anal anastomosisVenkateswaran NWeismiller SClarke KDove Medical Pressarticleindeterminate colitismedical treatmentulcerative colitiscrohn’s diseasetotal proctocolectomyileal pouch-anal anastomosisPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 6383-6395 (2021)
institution DOAJ
collection DOAJ
language EN
topic indeterminate colitis
medical treatment
ulcerative colitis
crohn’s disease
total proctocolectomy
ileal pouch-anal anastomosis
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
spellingShingle indeterminate colitis
medical treatment
ulcerative colitis
crohn’s disease
total proctocolectomy
ileal pouch-anal anastomosis
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Venkateswaran N
Weismiller S
Clarke K
Indeterminate Colitis – Update on Treatment Options
description Niranjani Venkateswaran,1 Scott Weismiller,1 Kofi Clarke2 1Division of General Internal Medicine, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USA; 2Division of Gastroenterology and Hepatology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA, USACorrespondence: Kofi ClarkeDivision of Gastroenterology and Hepatology, Department of Medicine, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA, 17033, USATel +1 717-531-8741Fax +1 717-531-6770Email kclarke@pennstatehealth.psu.eduAbstract: Indeterminate colitis (IC) is described in approximately 5– 15% of patients with inflammatory bowel disease (IBD). It usually reflects a difficulty or lack of clarity in distinguishing between ulcerative colitis (UC) and Crohn’s disease (CD) on biopsy or colectomy specimens. The diagnostic difficulty may explain the variability in the reported prevalence and incidence of IC. Clinically, most IC patients tend to evolve over time to a definite diagnosis of either UC or CD. IC has also been interchangeably described as inflammatory bowel disease unclassified (IBDU). This review offers an overview of the available limited literature on the conventional medical and surgical treatments for IC. In contrast to the numerous studies on the medical management of UC and CD, there are very few data from dedicated controlled trials on the treatment of IC. The natural evolution of IC more closely mimics UC. Regarding medical options for treatment, most patients diagnosed with IC are treated similarly to UC, and treatment choices are based on disease severity. Others are managed similarly to CD if there are features suggestive of CD, including fissures, skin tags, or rectal sparing. In medically refractory IC, surgical treatment options are limited and include total proctocolectomy (TPC) and ileal pouch–anal anastomosis (IPAA), with its associated risk factors and complications. Post-surgical complications and pouch failure rates were historically thought to be more common in IC patients, but recent meta-analyses reveal similar rates between UC and IC patients. Future therapies in IBD are focused on known mechanisms in the disease pathways of UC and CD. Owing to the lack of IC-specific studies, clinicians have traditionally and historically extrapolated the data to IC patients based on their symptomatology, clinical course, and endoscopic findings.Keywords: indeterminate colitis, medical treatment, ulcerative colitis, Crohn’s disease, total proctocolectomy, ileal pouch–anal anastomosis
format article
author Venkateswaran N
Weismiller S
Clarke K
author_facet Venkateswaran N
Weismiller S
Clarke K
author_sort Venkateswaran N
title Indeterminate Colitis – Update on Treatment Options
title_short Indeterminate Colitis – Update on Treatment Options
title_full Indeterminate Colitis – Update on Treatment Options
title_fullStr Indeterminate Colitis – Update on Treatment Options
title_full_unstemmed Indeterminate Colitis – Update on Treatment Options
title_sort indeterminate colitis – update on treatment options
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/874a0d0a449f4db6a25aff55a1d8e405
work_keys_str_mv AT venkateswarann indeterminatecolitisndashupdateontreatmentoptions
AT weismillers indeterminatecolitisndashupdateontreatmentoptions
AT clarkek indeterminatecolitisndashupdateontreatmentoptions
_version_ 1718406336853573632